Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials
暂无分享,去创建一个
[1] J. Baselga,et al. European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF) , 2005 .
[2] A. Brufsky,et al. Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support , 2005 .
[3] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Earl,et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] N. Gebbia,et al. FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] J. Blohmer,et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Hortobagyi,et al. Breast conservation after neoadjuvant chemotherapy , 2005, Cancer.
[8] J. Ioannidis,et al. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.
[9] M. Dowsett,et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] Roman Rouzier,et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Hortobagyi,et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] I. Zuna,et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] M. Buyse,et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] L. Brunereau,et al. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[15] D. Wallwiener,et al. Neoadjuvant endocrine therapy in primary breast cancer. , 2004, Clinical breast cancer.
[16] G. Hortobagyi,et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Mankoff,et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2004, Academic radiology.
[18] G. Hortobagyi,et al. Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience , 2004 .
[19] R. Kreienberg,et al. Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Terry L. Smith,et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] G. Hortobagyi,et al. Proceedings of the Consensus Conference on Neoadjuvant Chemotherapy in Carcinoma of the Breast, April 26–28, 2003, Philadelphia, Pennsylvania , 2004 .
[22] J. Stec,et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. Jakesz,et al. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. , 2004, Anticancer research.
[24] Matthew J Ellis,et al. Neoadjuvant Endocrine Therapy as a Drug Development Strategy , 2004, Clinical Cancer Research.
[25] B. Asselain,et al. Short and long‐term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial , 1999, Breast Cancer Research and Treatment.
[26] A. Hutcheon,et al. Neoadjuvant Docetaxel in Locally Advanced Breast Cancer , 2004, Breast Cancer Research and Treatment.
[27] M. Ellis. Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy , 2004, Annals of surgical oncology.
[28] T. Petit,et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. , 2004, European journal of cancer.
[29] S. Hilsenbeck,et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. , 2003, Clinical breast cancer.
[30] J. Dixon,et al. Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research. , 2003, Surgical oncology.
[31] D. Wickerham,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Darrell N. Smith,et al. 397 Preoperative trastuzumab and vinorelbine (HN) is a well-tolerated, active regimen for Her2 3+/FISH+stage II/III breast cancer , 2003 .
[33] H. Dressman,et al. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[34] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[35] E. Mamounas. Sentinel lymph node biopsy after neoadjuvant systemic therapy. , 2003, The Surgical clinics of North America.
[36] Hans-Peter Sinn,et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] P. Bruzzi,et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] Barbara L. Smith,et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] S. Steinberg,et al. Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial , 2003, Annals of Surgical Oncology.
[42] L. Walker,et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. , 2002, Clinical breast cancer.
[43] Fiona J Gilbert,et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] A. Vincent-Salomon,et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] D. Wickerham,et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.
[46] J. Bryant,et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.
[47] C. V. D. van de Velde,et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] M. Ellis,et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] W. Eiermann,et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] R. Gray,et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[52] P. Ravdin,et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] I. Smith,et al. Neoadjuvant chemotherapy for breast cancer , 2000, Annals of medicine.
[54] G. Hortobagyi,et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] K. Friedrichs,et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] J. Bergh,et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. , 1999, European journal of cancer.
[57] M. Tattersall,et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] G. Hortobagyi,et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. , 1999, Annals of surgery.
[59] D. Richel,et al. Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy , 1999 .
[60] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] G. MacGrogan,et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[62] T. Powles,et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] V Torri,et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[65] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] F. Bonichon,et al. Résultats à 10 ans d'un essai randomisé de chimiothérapie néo-adjuvante dans les cancers du sein de plus de 3 cm , 1998 .
[67] L. Mauriac,et al. [Results of 10 years of a randomized trial of neoadjuvant chemotherapy in breast cancers larger than 3 cm]. , 1998, Chirurgie; memoires de l'Academie de chirurgie.
[68] D. Wickerham,et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] G. Hortobagyi,et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center , 1997, Cancer Chemotherapy and Pharmacology.
[70] M. Espié,et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] G. Hortobagyi,et al. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. , 1995, Surgical oncology clinics of North America.
[72] G. Bonadonna,et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.
[73] V. Semiglazov,et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[74] S. Ebbs,et al. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. , 1993, British Journal of Cancer.
[75] G. Bonadonna. Evolving concepts in the systemic adjuvant treatment of breast cancer. , 1992, Cancer research.
[76] A. Luini,et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. , 1990, Journal of the National Cancer Institute.
[77] N Gunduz,et al. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. , 1983, Cancer research.
[78] G. Hortobagyi,et al. Multimodal treatment of locoregionally advanced breast cancer , 1983, Cancer.
[79] Josef Korinek,et al. Proceedings of the American Society of Clinical Oncology , 1982 .
[80] N Gunduz,et al. Effect of surgical removal on the growth and kinetics of residual tumor. , 1979, Cancer research.
[81] B. Fisher. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer , 1977, Cancer.
[82] F. Rosato,et al. Diseases of the Breast , 1972 .
[83] H. Skipper,et al. Kinetics of mammary tumor cell growth and implications for therapy , 1971, Cancer.